BenzingaOctober 19, 2026 at 3:31 AM NY8 Days Ago
Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
